Last reviewed · How we verify
CIML NK Cell Infusion
At a glance
| Generic name | CIML NK Cell Infusion |
|---|---|
| Also known as | cytokine induced memory-like natural killer |
| Sponsor | Washington University School of Medicine |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- CIML NK Cells With Venetoclax for AML (PHASE1)
- Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer (PHASE1)
- CIML NK Cell in Head & Neck Cancer (PHASE1)
- Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Acute Myeloid Leukemia (AML) (PHASE1, PHASE2)
- A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia (PHASE1)
- Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma (EARLY_PHASE1)
- A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation (PHASE1)
- Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |